- Yossi Amino's Space Pharma developing autonomous 'lab-on-a-chip' technology for microgravity experiments.
- Breakthroughs include growing skin, 'ribeye steak,' and developing self-releasing cancer treatments in space.
- Inbal Sheinfeld highlights Atlas Award as a crucial platform for innovative Israeli startups to gain global exposure and investment.
A recent conference session brought together pioneering space biotech and the prestigious Atlas Award, showcasing Israel's relentless drive for innovation. From developing autonomous labs in orbit to fostering groundbreaking startups, the discussion painted a vivid picture of a future shaped by advanced technology.
Yossi Amino, founder and CEO of Space Pharma, unveiled his company's revolutionary work in space biotechnology. Inspired by his military experience with satellite systems, Amino's vision led to the creation of miniature, autonomous 'lab-on-a-chip' devices designed for biological and chemical experiments in zero gravity. These credit card-sized labs, operating 400-530 kilometers above Earth, leverage the unique properties of microgravity – where elements behave differently without gravitational pull – to achieve results impossible on Earth. Space Pharma has already conducted nearly 75 experiments across 12 space flights, growing skin for cosmetic and reconstructive purposes, and even producing the first remotely controlled 'ribeye steak' tissue.
Looking ahead, Amino revealed plans for a groundbreaking biological plaster capable of detecting and automatically treating cancer within the body, marking a shift from science fiction to science fact. He also touched upon the future integration of AI as more space data becomes available, and the potential for bio-data centers in orbit. Despite challenges like launch delays, Space Pharma is moving towards mass production of pharmaceuticals in space, with an experimental factory for special crystals slated for late 2027. This innovative approach promises to revolutionize medicine, making advanced treatments more accessible and reducing the need for hospital visits.
The session also featured Inbal Sheinfeld, CEO of Bizon and an Atlas Award committee member, who underscored the award's significance. The Atlas Award, supported by the Ayn Rand Center in Israel, is not a cash prize but a vital platform offering managed exposure to venture capital and private equity firms in the US, Canada, and London. Sheinfeld emphasized that the award seeks companies with proven innovation in their DNA, requiring revenues over $1 million and valuations exceeding $10 million. Beyond financial metrics, the focus is on intellectual property (IP) and solving acute global problems, citing examples like Helios (iron production) and GIX (data accessibility).
Sheinfeld highlighted Israel's unique network effect, which continues to produce significant innovation despite recent challenges, attracting global VC firms. The Atlas Award acts as a crucial filter, elevating deserving startups above the 'noise signal ratio' and connecting them directly with serious investors. For entrepreneurs, she advised applying if their company meets the criteria, stressing that the award offers immense potential without requiring equity. The Atlas Junior program also nurtures young talent, ensuring a pipeline of future innovators in Israel's thriving tech ecosystem.
“We are essentially the first to bring life to space. There is no life there, at least no life patterns or life that we can identify.”
- Natalie Rotem, Host
